Evidence map›Paper›PMID 36232484›Full record

ArticleInternational journal of molecular sciences2022

Analysis of the Effects of Ninjin'yoeito on Physical Frailty in Mice.

Shotaro Otsuka, Keita Fukumaru, Akira Tani, Seiya Takada, Kiyoshi Kikuchi, Kosuke Norimatsu, Ryoma Matsuzaki, Teruki Matsuoka, Harutoshi Sakakima, Yuji Omiya and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. SGLT2 inhibitors: how do they affect the cardiac cells.Molecular and cellular biochemistry · 2025
    Review
  4. Article
  5. Article
  6. Advancements in Anti-Aging Treatment Development.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Shotaro OtsukaDepartment of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Science, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.ORCID 0000-0003-3563-2473
Keita FukumaruDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Akira TaniDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Seiya TakadaDepartment of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Science, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Kiyoshi KikuchiDepartment of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Science, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Kosuke NorimatsuDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Ryoma MatsuzakiDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Teruki MatsuokaDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Harutoshi SakakimaDepartment of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.ORCID 0000-0002-6805-2742
Yuji OmiyaTsumura Kampo Research Laboratories, Tsumura & Co., 3586 Yoshiwara, Ami-Machi 300-1192, Ibaraki, Japan.
Keita MizunoTsumura Kampo Research Laboratories, Tsumura & Co., 3586 Yoshiwara, Ami-Machi 300-1192, Ibaraki, Japan.
Yosuke MatsubaraTsumura Kampo Research Laboratories, Tsumura & Co., 3586 Yoshiwara, Ami-Machi 300-1192, Ibaraki, Japan.
Ikuro MaruyamaDepartment of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Science, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Kagoshima, Japan.
Kagoshima University · JPTsumura Research Institute (Japan) · JPKurume University · JP

Funding

Research grant from Tsumura Co. No Number
6 · The paper itself

Abstract

Physical frailty is an aging-related clinical syndrome involving decreases in body weight, mobility, activity, and walking speed that occurs in individuals with sarcopenia and is accelerated by increased oxidative stress. Ninjin'yoeito, a traditional Japanese Kampo medicine, is used for treating conditions, including anemia and physical weakness. Here, we investigated whether ninjin'yoeito could improve physical frailty by controlling oxidative stress in the senescence-accelerated mouse prone 8 (SAMP8) model. First, SAMP8 mice were divided into two groups, ninjin'yoeito treated and untreated, with the former consuming a diet containing 3% ninjin'yoeito from 3 months of age. At 7 months of age, body weight, motor function, locomotor activity, and mean walking speed were measured. Subsequently, mice were euthanized and measured for muscle weight, 8-hydroxy-2'-deoxyguanosine levels in muscle and brain, and cleaved caspase-3 expression in brain. The results showed reductions in weight, locomotor function, locomotion, and average walking speed in the untreated group, which were significantly improved by ninjin'yoeito. Furthermore, 8-hydroxy-2'-deoxyguanosine levels were reduced in muscle and brain from ninjin'yoeito-treated mice, compared with the levels in untreated mice; cleaved caspase-3 expression was similarly reduced in brain from the treated mice, indicating reduced apoptosis. Our findings suggest that ninjin'yoeito inhibits sarcopenia-based physical frailty through its antioxidant effects.

Indexed as

FrailtySarcopenia8-Hydroxy-2'-DeoxyguanosineAnimalsAntioxidantsBody WeightCaspase 3Disease Models, AnimalDrugs, Chinese HerbalMice8-Hydroxy-2'-DeoxyguanosineAntioxidantsCaspase 3Drugs, Chinese Herbalninjin'yoeito8-hydroxy-2′-deoxyguanosineninjin’yoeitophysical frailtySAMP8

Identifiers

PMID36232484
PMCPMC9569708
OpenAlexW4297008404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.